Evidence map›Paper›PMID 33037589›Full record

ArticleJournal of general internal medicine2021

Difficulty with Taking Medications Is Associated with Future Diagnosis of Alzheimer's Disease and Related Dementias.

Douglas Barthold, Zachary A Marcum, Shuxian Chen, Lindsay White, Nagham Ailabouni, Anirban Basu, Norma B Coe, Shelly L Gray

Open access · bronzeAbstract read
In one paragraph

Article in Journal of general internal medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Difficulty Taking Medications: a Corollary to Dementia Risk.Journal of general internal medicine · 2021
    Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Douglas BartholdThe Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, School of Pharmacy, University of Washington, Seattle, WA, USA. barthold@uw.edu.ORCID 0000-0003-0511-5520
Zachary A MarcumThe Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, School of Pharmacy, University of Washington, Seattle, WA, USA.
Shuxian ChenThe Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, School of Pharmacy, University of Washington, Seattle, WA, USA.
Lindsay WhiteRTI International, Seattle, WA, USA.
Nagham AilabouniThe Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, School of Pharmacy, University of Washington, Seattle, WA, USA.
Anirban BasuThe Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, School of Pharmacy, University of Washington, Seattle, WA, USA.
Norma B CoeDepartment of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Shelly L GrayThe Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, School of Pharmacy, University of Washington, Seattle, WA, USA.
University of Washington · USRTI International · USUniversity of Pennsylvania · USUniversity of South Australia · AU

Funding

HRS Yrs29-34: Y33 SSA CoFundingU01AG009740 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Jessica Faul, KENNETH M LANGA · 1990 to 2026
$555.8M
Furthering scientific understanding of mechanisms underlying resilience to the effects of AD pathology by incorporating state of the art quantification of gliosis, inflammation, & synaptic toxicityU01AG006781 · NIA · UNIVERSITY OF WASHINGTON · PI CRANE, PAUL K, LARSON, ERIC B · 1986 to 2020
$39.3M
Model for Economic Analysis of Sickle cell cURE (MEASURE)OT3HL152448 · NHLBI · UNIVERSITY OF WASHINGTON · PI BASU, ANIRBAN · 2019 to 2019
$3.3M
Value of Information Methods for NHLBI TrialsR01HL126804 · NHLBI · UNIVERSITY OF WASHINGTON · PI BASU, ANIRBAN · 2015 to 2018
$2.7M
Effectiveness of Gastric Sleeve vs. Gastric Bypass for Cardiovascular DiseaseR01HL130462 · NHLBI · KAISER FOUNDATION RESEARCH INSTITUTE · PI COLEMAN, KAREN JACQUELINE · 2016 to 2019
$2.7M
Acceptability of Sustained-Release Antiretrovirals for Treatment in the US and sub-Saharan AfricaR01MH121424 · NIMH · UNIVERSITY OF WASHINGTON · PI GRAHAM, SUSAN MARIE · 2019 to 2023
$2.4M
Current and Future Costs of Alzheimer's and Dementia CareR01AG049815 · NIA · UNIVERSITY OF WASHINGTON · PI COE, NORMA B · 2015 to 2018
$2.1M
Antihypertensives and the Aging BrainK76AG059929 · NIA · UNIVERSITY OF WASHINGTON · PI MARCUM, ZACHARY ADAM · 2019 to 2021
$694k
ACL HHS U01CE002967CDC HHS U01CE002967NCIPC CDC HHS U01 CE002967NHLBI NIH HHS 1OT3HL152448NHLBI NIH HHS OT3 HL152448NHLBI NIH HHS R01 HL126804NHLBI NIH HHS R01HL126804NHLBI NIH HHS R01 HL130462NIA NIH HHS 1R01AG049815NIA NIH HHS K76 AG059929NIA NIH HHS K76AG059929NIA NIH HHS R01 AG049815NIA NIH HHS U01 AG006781NIA NIH HHS U01AG006781NIA NIH HHS U01 AG009740NIH HHS R01HL130462NIH HHS R01MH121424NIMH NIH HHS R01 MH121424
6 · The paper itself

Abstract

backgroundMedication management requires complex cognitive functioning, and therefore, difficulty taking medications might be an early sign of cognitive impairment and could be a risk factor for Alzheimer's disease and related dementias (ADRD). Accordingly, people with difficulty taking medications may benefit from more detailed cognitive screening, potentially aiding in the diagnosis of ADRD, which is underdiagnosed. We are unaware of evidence on medication management difficulties that precede a real-world ADRD diagnosis in the USA.

objectiveExamine the association between difficulty taking medications and subsequent real-world ADRD diagnoses.

designCase-control study, using Health and Retirement Study (HRS) survey data linked to Medicare claims.

participantsA total of 1461 HRS respondents with an ADRD diagnosis observed from 1993 to 2012 (cases), matched by year of birth, wave of HRS entry, and sex to 3771 controls with no ADRD diagnosis. MAIN MEASURES: We examined the association between diagnosis of ADRD and self-reported difficulty taking medications in the preceding years (1-2 and 3-4 years prior to case definition). Control individuals were assigned the index date from their matched case. Conditional logistic regressions adjusted for age, sex, race, education, and comorbidities. KEY

resultsCompared with matched controls, cases had higher prevalence of difficulty taking medications 1-2 years prior to diagnosis (11.0% versus 2.3%), and 3-4 years prior to diagnosis (5.8% versus 2.3%). Adjusted analyses showed that compared with individuals without ADRD, those with an ADRD diagnosis had more than four times higher odds of difficulty taking medications 1-2 years prior (OR = 4.56 (CI 3.30-6.31)), and more than two times higher odds of difficulty taking medications 3-4 years prior (OR = 2.41 (CI 1.61-3.59)).

conclusionsOdds of medication difficulty 1-2 years prior were more than four times greater for individuals with ADRD diagnoses compared with those without ADRD. Medication management difficulties may prompt further cognitive screening, potentially aiding in earlier recognition of ADRD.

Indexed as

Alzheimer DiseaseCognitive DysfunctionAgedCase-Control StudiesComorbidityHumansMedicareUnited StatesAlzheimer’s disease and related dementiascognitive screeningmedication management

Identifiers

PMID33037589
PMCPMC8041972
OpenAlexW3092328433

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.